IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of non-qualified stock options to a newly hired employee. The Compensation Committee approved options to purchase 150,000 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan. These options, granted on August 19, 2024, have an exercise price of $39.06 per share, matching the closing price of IDEAYA's stock on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato l'assegnazione di opzioni su azioni non qualificate a un nuovo dipendente assunto. Il Comitato per la Compensazione ha approvato opzioni per l'acquisto di 150.000 azioni di azioni ordinarie nell'ambito del Piano di Incentivazione per l'Occupazione 2023 dell'azienda. Queste opzioni, concesse il 19 agosto 2024, hanno un prezzo di esercizio di $39,06 per azione, corrispondente al prezzo di chiusura delle azioni di IDEAYA alla data di concessione. Le opzioni hanno un termine di 10 anni e si matureranno in quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei successivi tre anni, a condizione di continuare l'impiego.
IDEAYA Biosciences (NASDAQ: IDYA) ha anunciado la concesión de opciones sobre acciones no calificadas a un nuevo empleado contratado. El Comité de Compensación aprobó opciones para comprar 150,000 acciones de acciones ordinarias bajo el Plan de Incentivos por Empleo 2023 de la empresa. Estas opciones, concedidas el 19 de agosto de 2024, tienen un precio de ejercicio de $39.06 por acción, igualando el precio de cierre de las acciones de IDEAYA en la fecha de concesión. Las opciones tienen un plazo de 10 años y se consolidarán en cuatro años, con el 25% consolidándose después de un año y el 75% restante consolidándose mensualmente durante los tres años siguientes, sujeto a la continuidad del empleo.
IDEAYA Biosciences (NASDAQ: IDYA)는 새로 고용된 직원에게 비자격 주식 옵션을 부여한다고 발표했습니다. 보상 위원회는 회사의 2023 고용 유인 인센티브 상여 계획에 따라 150,000주의 보통주를 구매할 수 있는 옵션을 승인했습니다. 2024년 8월 19일에 부여된 이 옵션은 주당 $39.06의 행사 가격을 가지고 있으며, 이는 부여일의 IDEAYA 주식 종가와 일치합니다. 이 옵션은 10년의 유효기간을 가지며 4년에 걸쳐 발생합니다. 1년 후 25%가 발생하고 나머지 75%는 이후 3년 동안 매달 발생합니다. 이는 계속 고용되어야 합니다.
IDEAYA Biosciences (NASDAQ: IDYA) a annoncé l'octroi d'options d'achat d'actions non qualifiées à un nouvel employé recruté. Le Comité de Rémunération a approuvé des options pour acheter 150 000 actions ordinaires dans le cadre du Plan d'Incentives d'Emploi 2023 de l'entreprise. Ces options, accordées le 19 août 2024, ont un prix d'exercice de 39,06 $ par action, correspondant au prix de clôture de l'action IDEAYA à la date de l'octroi. Les options ont une durée de 10 ans et se concrétiseront sur quatre ans, avec 25 % se concrétisant après un an et les 75 % restants se concrétisant mensuellement pendant les trois années suivantes, sous réserve de la continuité de l'emploi.
IDEAYA Biosciences (NASDAQ: IDYA) hat die Gewährung von nicht qualifizierten Aktienoptionen an einen neu eingestellten Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte Optionen zum Kauf von 150.000 Aktien von Stammaktien im Rahmen des 2023 Anreizplans für Arbeitsnehmer des Unternehmens. Diese Optionen, die am 19. August 2024 gewährt wurden, haben einen Ausübungspreis von 39,06 USD pro Aktie, der dem Schlusskurs der IDEAYA-Aktien am Gewährungstag entspricht. Die Optionen haben eine Laufzeit von 10 Jahren und vallen über vier Jahre, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über die folgenden drei Jahre fällig werden, vorausgesetzt, dass die Beschäftigung fortgesetzt wird.
- Granting of stock options may help attract and retain talent
- Exercise price aligns with current market value, potentially motivating employee performance
- Potential dilution of existing shareholders' equity
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302229039.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
How many stock options did IDEAYA Biosciences (IDYA) grant on August 19, 2024?
What is the exercise price for the stock options granted by IDEAYA Biosciences (IDYA)?
What is the vesting schedule for the stock options granted by IDEAYA Biosciences (IDYA)?
Under which plan were the stock options granted by IDEAYA Biosciences (IDYA)?
